Onzin is a small, novel, and highly conserved protein with unique structure and tissue-restricted expression. The regulation of its expression and biological roles remain greatly elusive. Here, we provide the first demonstration that onzin expression is significantly downregulated during differentiation induction of acute myeloid leukemic (AML) cell lines and primary cells by all-trans retinoic acid (ATRA) and especially by phorbol 12-myristate 13-acetate (PMA). Applying chemical inhibitions, RNA interferences, and transfected expressions of dominant negative mutants or constitutive catalytic forms of the related kinases, we show that protein kinase C-e (PKCe)-extracellular signal-regulated protein kinase 2 (ERK2) signaling axis is required for PMA-induced downregulation of onzin expression. The ectopic expression of onzin partially inhibits PMA-induced monocytic differentiation of AML cells, whereas suppression of onzin by specific short hairpin RNAs enhances PMA-induced differentiation to a degree. Furthermore, onzin partially inhibits the transcriptional activity of hematopoiesisrelated important transcription factor PU.1 via their interaction. Taken together, our results show that PMA downregulates onzin expression through PKCe-ERK2 signaling pathway, which favors monocytic differentiation of leukemic cells.
Introduction
Acute myeloid leukemia (AML), a class of prevalent hematopoietic malignancies, is characterized by complete or partial blockage at different stages of differentiation of myeloid progenitor cells, together with deregulated proliferation and a survival advantage of hematopoietic progenitors. 1 In the past 20 years, it has been attracting great attentions to understand the mechanisms on the AML cell differentiation, and significant progresses have been gained. Some groups including ours showed that phospholipid scramblase 1 (PLSCR1), a multiply palmitoylated, calcium-binding, lipid raft-associated endofacial plasma membrane protein, contributes to AML cell differentiation induced by all-trans retinoic acid (ATRA), phorbol 12-myristate 13-acetate (PMA), and wogonin, which is possibly mediated by protein kinase C-d (PKCd). 2, 3 More recently, PLSCR1 was identified to interact with onzin, a small, highly conserved, cysteine-rich protein with unique structure and tissue-restricted expression, 4, 5 and depletion of endogenous PLSCR1 in myeloid cells leads to a phenotype that mimics that of onzin overexpression. 6 On the basis of these discoveries, here we ask whether and how onzin exerts a role in leukemic cell differentiation.
Materials and methods

Cell lines, primary cells, and differentiation assay
Primary leukemic cells were isolated from bone marrow of four cases of AML (one case of AML-M3, two cases of AML-M4, and one case of AML-M5a according to the French-AmericanBritish classification) by Ficoll-Hypaque (GE healthcare, Uppsala, Sweden). The patients were diagnosed by morphologic criteria together with genetic aberrations and immunophenotyping analysis. Before sample collection, all patients did not receive any treatment. All manipulations were consented by patients and approved by Medical Science Ethic Committee of SJTU-SM. These primary cells, leukemic NB4 and U937 cell lines as well as other cell lines were cultured and treated as described in Supplementary Information. Cell differentiation was evaluated by morphology, CD11b/CD14 expression, and nitroblue tetrazolium (NBT) reduction assay (see Supplementary Information), and cell apoptosis was evaluated by annexin V assay on flow cytometry.
Plasmids, short hairpin RNAs, and transfection
Hemagglutinin (HA)-tagged plasmids pHACB-PKCbII-DN (for Dominant Negative), pHACE-PKCe-DN, pHACB-PKCbII-CAT (for Constitutive AcTivated) and pHACE-PKCe-CAT were generous gifts from Dr Jae-Won Soh in Inha University, Incheon, Korea. These plasmids were transfected into HeLa cells using Polyfect transfection reagent (Qiagen, Valencia, CA, USA). NB4 cells with stable onzin overexpression were generated by retrovirus infections according to the description in Supplementary Information. To knock-down expression of onzin in U937, two pairs of complementary short hairpin (sh)RNAs against onzin (onzin-sh2 and onzin-sh3) were synthesized, annealed, and ligated into pSIREN-RetroQ vector (Clontech, Palo Alto, CA, USA), and transfected into U937 cells by retrovirus infection. To knock-down extracellular signal-regulated protein kinase (ERK)1, ERK2, PKCb, PKCd, and PKCe expression, the specific shRNAs against target kinases as well as non-target shRNA control (NC) constructed in pLKO.1-puro vectors from Sigma (St Louis, MO, USA) were, respectively, co-transfected with packaging plasmids pCMVDR8.91 and pMD.G into 293T cells to produce lentivirus. Supernatants containing lentiviruses were collected 48 h after transfection and were used to infect U937 cells. The stable transformants were selected by testing targeted proteins. The target sequence for all these genes are provided in Supplementary Table S1 .
Real-time quantitative and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) Total RNA was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA), followed by treatment with RNase-free DNase (Promega, Madison, WI, USA). RT-PCR was performed with Promega RNA PCR kit following the manufacturer's instruction. Real-time PCR was performed and data were analyzed as described earlier. 2 The specific primers for realtime PCR were given in the Supplementary Information. Detection of onzin mRNA levels by semiquantitative RT-PCR was performed with Takara PCR kit (Takara, Dalian, China) following the manufacturer's instruction.
Onzin antibody production and co-immunoprecipitation Escherichia coli BL21 (DE3) expressed onzin protein was used to immunize New Zealand White rabbit to raise antibody against onzin. The antibody was affinity purified by ImmunoPure IgG Purification Kit (Pierce, Rockford, IL, USA) and the specificity was assessed by western blot analysis. For the co-immunoprecipitation (IP) experiments, cell extracts were incubated with antibodies against GFP (Becton Dickinson, Palo Alto, CA, USA), PU.1, C/EBPa (Santa Cruz Biotech, Santa Cruz, CA, USA) or onzin together with protein A plus-agarose (Santa Cruz Biotech) or incubated with mouse anti-Flag M2-agarose gel (Sigma-Aldrich) overnight at 4 1C. Normal preimmune mouse and rabbit IgG (Santa Cruz Biotech) were also used as negative controls. The immunoprecipitates were eluted by the 2 Â sodium dodecyl sulfate (SDS) sample buffer and then detected by western blots.
Luciferase assay
293T cells were seeded in 12-well plate (Becton Dickinson, Franklin Lakes, NJ, USA), and transfected with 100 ng of pFlag-CMV4-Runx1, pcDNA3-C/EBPa, or pcDNA-PU.1 together with pM-CSFR-luciferase(Luc) (100 ng), a luciferase reporter construct containing Runx1, C/EBPa, and PU.1 responding element of the promoter of M-CSFR gene and pTK-Renilla (10 ng) in the presence or absence of pFlag-CMV4-onzin. The empty vectors were used to supplement to 1000 ng of the total plasmid concentration. After 24 h, cell lysates were analyzed by the Dual-Luciferase Assay system (Promega) according to the manufacturer's instruction. The relative luciferase activity was normalized by renilla activity.
Western blot
Cell lysates were equally loaded to 10 or 15% SDS-polyacrylamide gel and immunoblots were performed with primary antibodies as described in Supplementary Information. Then, the blots were incubated by horseradish peroxidase (HRP)-linked secondary antibody (Cell Signaling, Beverly, MA, USA) for 1 h at room temperature. The signals were detected by chemiluminescence phototope-HRP kit (Pierce) according to the manufacturer's instructions.
Statistical analysis
All experiments were repeated at least three times with the similar results. The Student's t-test was used to compare the difference between the two groups. A P-value of o0.05 was considered to be statistically significant.
Results
Onzin expression is downregulated by PMA and ATRA in cell lines and primary AML cells
Acute monocytic leukemic U937 cell line was treated with various concentrations of PMA for 24 h, and onzin protein and mRNA were detected by western blot and real-time quantitative PCR, respectively. The results revealed that PMA significantly reduced onzin protein, which could be seen and became maximal, respectively, under treatment of PMA at 1 and 5 nM (Figure 1a, left) . When U937 cells were treated with 10 nM of PMA for 3 days, onzin protein became undetectable (Figure 1a , right). PMA also significantly downregulated onzin mRNA level (Figure 1b) . Actinomycin-D inhibition test showed that PMA treatment decreased onzin mRNA stability in U937 cells (Supplementary Figure S1) . The inhibitory effects of PMA on mRNA and protein expressions of onzin could also be seen in acute promyelocytic leukemic NB4 cell line (Supplementary Figure S2A and B) as well as four solid tumor cell lines with endogenous onzin expression (Supplementary Figure S3) .
In addition, 10 À6 M of ATRA, a clinically useful differentiation inducer, also effectively decreased expression of onzin mRNA and protein in a time-dependent manner ( Figure 1c ). Both ATRA at 10 À6 M and PMA at 10 nM also decreased onzin protein expression in primary cells from four AML patients (Figure 1d ), which seemed consistent with their differentiation-inducing extent as estimated by CD11-positive cells percentage (Supplementary Figure S4 ). Of note, it appeared that 10 nM of PMA presented stronger inhibitory effect on onzin expression in either U937 cell line or primary AML cells than 10 À6 M ATRA.
PKCe activation is responsible for PMA-reduced onzin expression
Considering PMA had stronger effect than ATRA in the downregulation of onzin expression, we used PMA as a probe to investigate the potential mechanisms of onzin downregulation in the following experiments. Earlier, it was shown that c-Myc is a negative regulator of onzin expression. 7 However, PMA treatment also decreased c-Myc expression in leukemic and solid tumor cells tested (Supplementary Figures S2 and S3 ), which should exclude the possibility that the suppression of onzin by PMA is caused by the negatively regulating effect of c-Myc on onzin expression. The above-described fact, that the suppression of onzin expression by PMA was cell typeindependent, proposed that the common mechanism(s) is involved in this event. As well known, PKC represents a major cellular receptor for PMA. 8 PKC comprises a family of phospholipid-dependent serine/threonine kinases, at least including 11 isoforms that have been divided into three groups based on their structures and cofactor requirements, that is, classical or conventional (a, bI, bII, and g), novel (d, e, Z, m, and y), and atypical (z, i/l) PKCs. 9 Consistent with the earlier reports, 10 PMA could activate/phosphorylate conventional (such as PKCb) and novel (such as PKCe) but not the atypical (such as PKCl) PKC isoforms, although prolonged exposure to PMA induces downregulation of PKCb/e (Supplementary Figure S5) . Hence, U937 cells were pretreated for 1 h with Ro 31-8220 (an effective inhibitor of PKCa, bI, bII, g, and e), Gö 6976 (an inhibitor of PKCa, bI, and m) or rottlerin (an inhibitor of PKCd), followed by 10 nM of PMA treatment for additional 24 h. The results showed that PMA-induced suppression of onzin expression could significantly be rescued by pretreatment of Ro 31-8220 (Figure 2a ), even at 1 mM, a much lower concentration (Supplementary Figure S6A) . However, Gö 6976 and rottlerin had no effects on PMA-reduced onzin expression (Figure 2a) . The knock-down of PKCd by shRNA also failed to rescue PMA-decreased onzin expression, although it could significantly block PMA-induced upregulation of PLSCR1 (Supplementary Figure S6B) , as reported earlier. 2, 11 On the basis of these results and the fact that PKCg only expresses in the neurons and vascular nerve endings, 12 we extrapolated that PKCe or/and PKCbII may be responsive for the downregulation of onzin expression in response to PMA treatment. To confirm this, their dominant negative mutants (DN) or constitutive activated forms (CAT) were transfected into HeLa cells for the convenience of transfections. The results showed that PKCe-DN but not PKCbII-DN almost completely overcame PMA-reduced onzin expression (Figure 2b ), whereas the transfected expression of PKCe-CAT instead of PKCbII-CAT directly decreased the expression of onzin protein (Figure 2c ). Consistent with these observations, the effective knock-down of PKCe by all three pairs of specific shRNAs successfully rescued PMA-induced onzin downregulation in U937 cells (Figure 2d ). Of note, the knock-down of PKC-b failed (Supplementary Figure S6B) . Collectively, these results strongly indicated that the activated PKCe contributes to PMA-induced onzin reduction.
ERK is the downstream effector of PKCe for PMA-induced suppression of onzin expression
As well established, 13 PKC isozymes activate the mitogenactivated protein kinase (MAPK), which consists of three main protein kinase families: ERKs, the c-Jun N-terminal kinases (JNKs), and the p38 family. Indeed, JNK, ERK, and p38 were rapidly phosphorylated on PMA treatment, although the activation of the former two kinases, especially JNK, was transient (Supplementary Figure S5) . To determine whether the activations of these MAPKs contribute to the suppression of onzin by PMA, U937 cells were treated with 10 nM PMA after pretreatment for 1 h with chemical inhibitors PD98059, SP600125, and SB203580, respectively, against ERK1/2, JNK, and p38. These inhibitors could effectively and rapidly inhibit the activation of the corresponding kinases (Figures 3a-c) . Of great importance, inhibition of ERK1/2 by PD98059 significantly rescued downregulation of onzin induced by PMA (Figure 3a) , whereas inhibition of JNK or p38 failed (Figures 3b and c) . In addition, the inhibition of ERK activation by U0126, another specific ERK inhibitor, also significantly blocked PMA-induced onzin downregulation in U937 cells (Figure 3d ). Later, we knocked down ERK expression by shRNAs specifically targeting ERK1 and ERK2. As depicted in Figure 3e , the shRNAs against ERK1 (ERK1-sh1 and ERK1-sh2) and ERK2 (ERK2-sh1 and ERK2-sh4), respectively, suppressed the ERK1 and ERK2 expression without reciprocal interference, suggesting the specificity for these shRNAs. Interestingly, ERK2 shRNAs greatly rescued PMA-decreased onzin expression while the ERK1 shRNAs failed (Figure 3f ), indicating ERK2 rather than ERK1 contributes to PMA-induced downregulation of onzin. Of note, the inhibition of PKCe activation by Ro 31-8220 and PKCe-DN transfection could block the phosphorylation of ERK (Figure 2b ; Supplementary Figure S6A ), whereas the inhibition of ERK by PD98059 or U0126 failed to affect the phosphorylation of PKCe during PMA induction (Figures 3a and d) . All these results suggested that ERK2 exerted a potential role as PKCe effectors for the suppression of onzin expression.
Onzin is a negative regulator for PMA-induced differentiation of AML cells
To investigate whether the downregulation of onzin expression is associated with leukemic cell differentiation, the full-length onzin cDNA together with empty vector as a control were, respectively, transfected into NB4 cells by retrovirus infection. NB4 cells with onzin infection expressed higher level of onzin protein, and the ectopically expressed onzin protein could sufficiently overcome the decrease of endogenous onzin protein induced by PMA (Figure 4a (Figures 4b and c) . Moreover, when treated with PMA for 24 h, empty vector-infected NB4 cells extended multiple podia and adhered onto culture dish plates (a hallmark of monocytic differentiation 14 ) , which was significantly inhibited by onzin overexpression (Figure 4d) . However, the effect of onzin overexpression on ATRA-induced granulocytic differentiation in NB4 cells is relative subtle, as assessed by CD11b/CD14-positive cells percentage, NBT reduction and morphology as well (Supplementary Figure S7B-D) . In addition, the forced expression of onzin also partially blocked PMA-induced differentiation of U937 cells, as evidenced by morphologic features and CD11b/CD14 expression (data not shown). By the way, the onzin overexpression cells had no effects on apoptotic induction by etoposide or tunicamycin in either U937 or NB4 cells (data not shown).
To further validate the role of onzin in myeloid cell differentiation, U937 cells were transfected by two pairs of shRNAs against onzin (onzin-sh2 and onzin-sh3), which significantly eliminated endogenous onzin protein (Supplementary Figure S8A ). Compared with NC transfected cells, more intriguingly, the suppression of onzin expression significantly enhanced PMA-induced CD11b and CD14 expression. Notably, it also enhanced ATRA-induced CD11b expression (Supplementary Figure S8B) . All these results suggested that onzin is a negative regulator for PMA-induced monocytic differentiation. 
Onzin physically interacts with and inhibits transcriptional activity of PU.1 protein
To exploit how onzin affects PMA-induced differentiation, we investigated whether onzin interacts with the Runt-related protein 1(Runx1), CCAAT/enhancer-binding protein a (C/EBPa) and PU.1, three important transcriptional factors in hematological cell differentiation. 15 Toward this end, Co-IP experiments were performed in 293T cells with co-transfection of GFP-onzin together with Flag-PU.1, Flag-Runx1, or Flag-C/EBPa. The results showed that part of Flag-PU.1 protein could be coprecipitated with GFP-onzin by anti-GFP antibody. Vice versa, GFP-onzin protein was also co-precipitated together with Flag-PU.1 protein by anti-Flag antibody (Figure 5a ), indicating the interaction of onzin with PU.1. However, GFP-onzin failed to interact with Flag-Runx1 or Flag-C/EBPa (Supplementary Figure S9) . The interaction was also detected in U937 cells, which express endogenous PU.1 and onzin. As can be visualized in Figure 5b , preimmune rabbit IgG failed to precipitate PU.1 or onzin protein, whereas anti-PU.1 or antionzin antibody pulled its targeted protein down, confirming the specificity and effectiveness of the Co-IP assay. Anti-onzin antibody was capable of precipitating endogenous PU.1 protein, whereas anti-PU.1 antibody failed to precipitate onzin protein.
We extrapolated that interaction of onzin with PU.1 possibly covered the epitope of the anti-PU.1 antibody.
Finally, 293T cells were transfected with Runx1/CBFb, C/EBPa, or PU.1 in the presence or absence of onzin, together with pM-CSFR-luc (driven by human macrophage colonystimulating factor receptor promoter containing Runx1, C/EBPa, and PU.1-binding sites) 16, 17 and pTK-renilla. In consistence with earlier reports, Runx1, C/EBPa, and PU.1 increased the M-CSFRluc activity, and onzin had no effect on M-CSFR-luc activity (Figure 6a) . Interestingly, onzin partially but statistically significantly decreased M-CSFR-luc activity driven by PU.1 
Discussion
Onzin presents tissue-limited expression, with high levels in phagocytes, macrophages, neutrophils, intestine, and spleen. 18 However, both the basis for the differential expression of onzin and its function remain greatly elusive. Here, we provide the first demonstration that two leukemic cell differentiationinducing agents ATRA and especially PMA significantly inhibited the expression of onzin in AML cell lines and primary cells as well as some onzin-expressing solid tumor cells. Under PMA and ATRA treatment, the decrease of onzin protein paralleled the downregulation of its mRNA. Further, PMA could significantly decrease the stability of onzin mRNA, of which mechanism remains to be further explored. Of note, it was reported that PMA can also directly regulate protein activity or protein-protein interaction. 19 Here, we cannot exclude the possibility that higher concentrations of PMA directly affects onzin protein, because its protein but not mRNA was partially restored under higher concentrations of PMA (Figure 1a) .
PMA has been reported to enhance or inhibit the expressions of a myriad of genes through multiple mechanisms. 20 The best known receptors for PMA are the novel and classical isotypes of PKCs, which link phorbol esters and the physiological second messenger diacylglycerol by the C1 domains. 21, 22 A series of evidence from the chemical inhibitions, RNA interferences, and transfections of dominant negative mutants and the constitutive activated forms of several representative PKCs strongly validated that PKCe is required for suppression of onzin expression by PMA. Furthermore, PKCs lead to the activation of the MAPK More recently, PKCe is also reported to have an essential role in the lactotroph proliferation induced by PMA by triggering signals that involve ERK1/2 activation. 26 Here, we showed that chemical inhibition or RNA interference of ERK2 could significantly block PMA-induced onzin downregulation. On the other hand, inhibition of PKCe activation by chemical inhibitor, its dominant negative mutants blocked ERK activation by PMA, suggesting that PKCe contributes to ERK activation and subsequently onzin suppression. Furthermore, we found that ERK2 rather than ERK1 was involved in this event. Totally, our results proposed that PMA inhibits the transcriptional expression of onzin gene through PKCe-ERK2 signaling cassette.
PMA is one of the classical differentiation-inducing agents for hematopoietic cells, and it induces leukemic cells to differentiate toward monocytic, macrophagic, or megakaryocytic phenotype. [27] [28] [29] There is emerging evidence that PKC subtypes have important functional roles in the regulation of differentiation of hematopoietic cells. 30 Also, there is a significant amount of evidence establishing distinct patterns of expression and function for different PKC isoforms in different leukemias. 31 The PKC isoform expression during hematopoiesis seems to be lineage specific, and individual PKC isoforms may have opposing functions. 32 The multifaceted nature of PKC biology is likely defined by many variables, including the nature of external stimuli and cell type, the downstream effectors and associated interacting proteins, and the isoform specificity, all of which have been shown to influence the direction of an eventual cellular response. PKCb was reported to be necessary and sufficient for PMA-induced differentiation of leukemic HL-60 cells 33, 34 however, only PKCa and d can participate in PMAinduced myeloid differentiation in the mouse myeloid progenitor 32D cell line. 35 PKCd is activated in an ATRA-dependent manner and has a role in the ATRA-induced differentiation of the leukemic NB4 and HL-60 cells, possibly by the association with retinoic acid receptor-a that bound to retinoic acid responsive element. 36 Earlier, we also showed that ATRA and PMA activated PKCd to upregulate PLSCR1, which presents an anti-leukemic effect by contributing its differentiation. 2, 37 More recently, the activation of PKCe and ERK signaling pathway is involved in myeloid lineage commitment. 27, 38 ERK signaling may have an important role in PMA-and ATRA-induced leukemia cell differentiation. [39] [40] [41] As reported by Lee's group, ERK2 activation is necessary for ATRA-induced differentiation. 39 Here, we also showed that the inhibition of ERK by U0126 could partially antagonize PMA and ATRA-induced differentiation of U937 cells (Supplementary Figure S10) . However, the mechanisms of these signaling molecules-contributed leukemic cell differentiation remain to be further explored. Hence, we investigated the possible role of the activated PKCe/ERK2-mediated downregulated onzin expression in leukemic cell differentiation. Our results showed that onzin overexpression significantly blocked PMA-induced monocytic differentiation in both NB4 and U937 cells. On the other hand, the suppression of onzin expression by specific shRNA enhanced PMA-and ATRA-induced differentiation in U937 cells. However, the effect of onzin overexpression on ATRA-induced granulocytic differentiation in NB4 cells was not significant, although a degree of inhibition could be seen. The phenomenum is consistent with the fact that the downregulation of onzin expression by ATRA was not so significant as that by PMA. These results suggested that onzin possibly has a role mainly in monocytic rather than granulocytic differentiation. In other words, the decrease of onzin would favor monocytic differentiation of leukemic cells. PU.1 has a pivotal role in hematopoietic cell differentiation and impaired PU.1 function is linked with leukemogenesis. 42, 43 PU.1 activates its own promoter, and turns on the three myeloid CSF (M, GM, and G-CSF) receptors, pushing cells along the pathway of myeloid differentiation. 15 Enhanced PU.1 activity favors monocytic commitment of the granulocyte-monocyte progenitor. 44 Proteins (such as Ski 45 ) and microRNAs (such as miR-424 46 ) are reported through interaction with PU.1 to antagonize or synergize its transcriptional activity and finally affect monocyte/macrophage differentiation. Here, we reported that onzin interacted with PU.1 and partially inhibited PU.1 transcriptional activity, which may explain how onzin negatively partially regulated PMA-induced leukemia cell differentiation.
By the way, inhibition of endogenous onzin was previously shown to result in a reduced growth rate and an increased sensitivity to apoptotic stimuli, whereas the enforced expression of onzin in fibroblasts, which normally express little or none of the protein, leads to marked apoptotic resistance and tumorigenic conversion through modulating Akt-Mdm2-p53 pathway. 7 However, our results showed that the forced expression or downregulation of onzin had no significant effect on apoptosis induction by etoposide or tunicamycin in either U937 or NB4 cells. We speculated that this is possibly because p53 is mutated in U937 cells 47 and inactivated in NB4 cells. 48 Taken together, our results show that onzin expression is significantly downregulated during differentiation induction of AML by ATRA and especially PMA through PKCe-ERK2 signaling axis. Of great importance, onzin negatively regulates AML cell differentiation, which is related to its inhibitory activity on the transcriptional activity of hematopoiesis-related transcription factor PU.1 via their interaction. These discoveries would shed new insights for understanding mechanisms of regulation of onzin expression and leukemic cell differentiation.
